This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2016 by Heikki Joensuu, Helsinki University Central Hospital
Scandinavian Sarcoma Group
Information provided by (Responsible Party):
Heikki Joensuu, Helsinki University Central Hospital Identifier:
First received: April 7, 2015
Last updated: March 4, 2016
Last verified: March 2016
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) and have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) for 2 more years (Arm A) or to stop imatinib (Arm B). The study participants are required to have histologically verified GIST with a high risk of GIST recurrence despite removal of all macroscopic GIST tissue at surgery and 3 years of adjuvant imatinib. The high risk of GIST recurrence is defined as one of the following: gastric GIST with mitotic count >10/50 high power fields (HPFs) of the microscope, non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture. Study participants allocated to Arm A will receive imatinib 400 mg/day for 24 months after the date of randomization. All study participants will be followed up using blood tests and computerized tomography (or MRI) of the abdomen. The computerized tomography examinations will be performed at 6 month intervals. A total of 300 patients will be entered to the study. The study hypothesis is that adjuvant imatinib given for a total of 5 years may prevent some of the GISTs to recur as compared to patients who receive adjuvant imatinib for 3 years, and there may be a difference in the rate of GIST recurrence between the two groups.

Condition Intervention Phase
Sarcoma Drug: Imatinib Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

Resource links provided by NLM:

Further study details as provided by Heikki Joensuu, Helsinki University Central Hospital:

Primary Outcome Measures:
  • Recurrence-free survival [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: 5 years ]
  • GIST-specific survival [ Time Frame: 5 years ]
  • Adverse effects [ Time Frame: 5 years ]
  • Quality of life [ Time Frame: 5 years ]

Estimated Enrollment: 300
Study Start Date: May 2015
Estimated Study Completion Date: May 2028
Estimated Primary Completion Date: May 2028 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Imatinib
Imatinib 400 mg/day for 24 months.
Drug: Imatinib
Imatinib 400 mg/day
Other Name: Gleevec
No Intervention: No imatinib
No further imatinib.

Detailed Description:
The study will accrue patients in several countries in the Europe.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years.
  • Morphological and immunohistological documentation of GIST (immunostaining for KIT and/or DOG-1 positive, or mutation of KIT or PDGFRA present in tumor tissue).
  • Macroscopically complete surgical resection of GIST (either R0 or R1 resection).
  • Mutation analysis of KIT and PDGFR genes has been carried out.
  • A high risk of GIST recurrence; either gastric GIST with mitotic count >10/50 HPFs, or non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture.
  • Eastern Cooperative Oncology Group performance status ≤ 2.
  • Adequate organ function.
  • Female patients of childbearing potential must have a negative pregnancy test within 14 days before initiation of study drug dosing. Postmenopausal women must have amenorrhea for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • Patient willing to be followed up at the study site regardless of the result of randomization.
  • Patient has provided a written, voluntary informed consent prior to study-specific screening procedures.

Exclusion Criteria:

  • Presence of distant metastases or local recurrence of GIST.
  • Not willing to donate tumor tissue and/or blood samples for the study molecular studies.
  • Presence of a substitution mutation at PDGFRA codon D842 (usually D842V).
  • Administration of adjuvant imatinib longer than for 3 years is planned regardless of the result of randomization, or "life long" imatinib administration is planned.
  • Prior adjuvant (+ neoadjuvant) therapy with imatinib mesylate for at least 35 months has not been completed, or the total duration of prior adjuvant (+ neoadjuvant) imatinib administration exceeds the total duration of 37 months.
  • Neoadjuvant imatinib for a duration that exceeds 9 months.
  • Longer than 4-week break during adjuvant imatinib administration.
  • The dose of imatinib at completion of 3 years of adjuvant imatinib was 200 mg per day or less or greater than 800 mg per day.
  • Patient has received any investigational anti-cancer agents during adjuvant imatinib or between completion of adjuvant imatinib and the date of randomization.
  • Patient has been free of another malignancy for less than 5 years except if the other malignancy is not currently clinically significant nor requiring active intervention, or if the other malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Recent existence of any other malignant disease is not allowed.
  • Patient with Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study entry).
  • Female patients who are pregnant or breast-feeding.
  • Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, severe chronic renal disease, or active uncontrolled infection).
  • Known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient with a significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02413736

Contact: Heikki Joensuu, MD 094711 ext 358
Contact: Raija Husa 094711 ext 358

Helsinki University Central Hospital Recruiting
Helsinki, Finland, 00029
Contact: Heikki Joensuu, MD    47173200 ext 09      
Contact: Raija Husa         
Sponsors and Collaborators
Heikki Joensuu
Scandinavian Sarcoma Group
Principal Investigator: Heikki Joensuu Helsinki University Central Hospital
  More Information

Responsible Party: Heikki Joensuu, Research Director, Helsinki University Central Hospital Identifier: NCT02413736     History of Changes
Other Study ID Numbers: SSGXXII
Study First Received: April 7, 2015
Last Updated: March 4, 2016

Additional relevant MeSH terms:
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on July 26, 2017